These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 34060787)
1. Lipid Lowering Is Beneficial for Secondary Prevention but Not Primary Prevention in Patients 75 Years and Older. Ebell MH Am Fam Physician; 2021 Jun; 103(11):695-696. PubMed ID: 34060787 [No Abstract] [Full Text] [Related]
2. Primary and secondary prevention of cardiovascular disease in patients with hyperlipoproteinemia (a). Grützmacher P; Öhm B; Szymczak S; Dorbath C; Brzoska M; Kleinert C Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):22-26. PubMed ID: 28233269 [TBL] [Abstract][Full Text] [Related]
3. Improving adherence to lipid-lowering therapy in a community pharmacy intervention program: a cost-effectiveness analysis. Vegter S; Oosterhof P; van Boven JF; Stuurman-Bieze AG; Hiddink EG; Postma MJ J Manag Care Spec Pharm; 2014 Jul; 20(7):722-32. PubMed ID: 24967525 [TBL] [Abstract][Full Text] [Related]
4. [Part I. Fibrates in primary and secondary prevention]. Clin Investig Arterioscler; 2016 Jul; 28 Suppl 3():3-10. PubMed ID: 27473465 [No Abstract] [Full Text] [Related]
5. Have we reached the bottom of the bottomless pit- lessons from the recent lipid-lowering trials? Bansal M; Agarwala R Indian Heart J; 2018; 70(3):331-334. PubMed ID: 29961445 [No Abstract] [Full Text] [Related]
6. Cardiovascular risk assessment and lipid modification: NICE guideline. Duerden M; O'Flynn N; Qureshi N Br J Gen Pract; 2015 Jul; 65(636):378-80. PubMed ID: 26120133 [No Abstract] [Full Text] [Related]
8. Association between triglycerides and cardiovascular events in primary populations: a meta-regression analysis and synthesis of evidence. Stauffer ME; Weisenfluh L; Morrison A Vasc Health Risk Manag; 2013; 9():671-80. PubMed ID: 24204156 [TBL] [Abstract][Full Text] [Related]
9. Landmark lipid-lowering trials in the primary prevention of cardiovascular disease. Chrispin J; Martin SS; Hasan RK; Joshi PH; Minder CM; McEvoy JW; Kohli P; Johnson AE; Wang L; Blaha MJ; Blumenthal RS Clin Cardiol; 2013 Sep; 36(9):516-23. PubMed ID: 23722477 [TBL] [Abstract][Full Text] [Related]
10. Prevention of cardiovascular disease: plea for a rationale use of diet and lipid-lowering drugs. Scheen AJ Acta Clin Belg; 2003; 58(3):149-51. PubMed ID: 12945473 [No Abstract] [Full Text] [Related]
11. Lipid-lowering therapy with statins for the primary and secondary prevention of cardiovascular disease. Lardizabal JA; Deedwania P Cardiol Clin; 2011 Feb; 29(1):87-103. PubMed ID: 21257102 [TBL] [Abstract][Full Text] [Related]
12. Dyslipidemia Part 2: Review of Dyslipidemia Treatment in Patients With Noncoronary Vascular Disease. Gonzalez L; Helkin A; Gahtan V Vasc Endovascular Surg; 2016 Feb; 50(2):119-35. PubMed ID: 26983668 [TBL] [Abstract][Full Text] [Related]
13. Severely frail elderly patients do not need lipid-lowering drugs. Mallery LH; Moorhouse P; McLean Veysey P; Allen M; Fleming I Cleve Clin J Med; 2017 Feb; 84(2):131-142. PubMed ID: 28198686 [TBL] [Abstract][Full Text] [Related]
14. Managing the dyslipidemia of metabolic syndrome: beyond statin therapy. Jialal I; Smith G Metab Syndr Relat Disord; 2012 Jun; 10(3):159-60. PubMed ID: 22568574 [No Abstract] [Full Text] [Related]
15. Aspirin for Primary and Secondary Prevention of Cardiovascular Disease. Godley RW; Hernandez-Vila E Tex Heart Inst J; 2016 Aug; 43(4):318-9. PubMed ID: 27547141 [No Abstract] [Full Text] [Related]
16. Statin Use and Adverse Effects Among Adults >75 Years of Age: Insights From the Patient and Provider Assessment of Lipid Management (PALM) Registry. Nanna MG; Navar AM; Wang TY; Mi X; Virani SS; Louie MJ; Lee LV; Goldberg AC; Roger VL; Robinson J; Peterson ED J Am Heart Assoc; 2018 May; 7(10):. PubMed ID: 29739801 [TBL] [Abstract][Full Text] [Related]
17. Statins: have we found the Holy Grail? Jeger R; Dieterle T Swiss Med Wkly; 2012; 142():w13515. PubMed ID: 22315166 [TBL] [Abstract][Full Text] [Related]
18. A Systematic Review of Cardiovascular Outcomes-Based Cost-Effectiveness Analyses of Lipid-Lowering Therapies. Wei CY; Quek RGW; Villa G; Gandra SR; Forbes CA; Ryder S; Armstrong N; Deshpande S; Duffy S; Kleijnen J; Lindgren P Pharmacoeconomics; 2017 Mar; 35(3):297-318. PubMed ID: 27785772 [TBL] [Abstract][Full Text] [Related]
19. Risk factors for primary prevention of cardiovascular disease and risk reduction by lipid control: the OMEGA study risk factor sub-analysis. Teramoto T; Kawamori R; Miyazaki S; Teramukai S; Mori Y; Okuda Y; Hiramatsu K; Clin Exp Hypertens; 2014; 36(4):236-43. PubMed ID: 23865387 [TBL] [Abstract][Full Text] [Related]
20. Statins in the primary and secondary prevention of cardiovascular disease in women: facts and myths. Virani SS Tex Heart Inst J; 2013; 40(3):288-9. PubMed ID: 23914021 [No Abstract] [Full Text] [Related] [Next] [New Search]